Form 4: Nurix Therapeutics CFO Hans van Houte Reports Stock Transactions
SEC Form 4 Filing
Hans van Houte, CFO of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.
Summary
- On October 30, 2024, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
- Van Houte acquired 2,886, 2,000 and 3,750 shares of common stock through the vesting of RSUs at a price of $0.
- Simultaneously, 2,368 shares were disposed of at a weighted average price of $24.305 to cover tax withholding obligations related to the vesting of RSUs.
- Following these transactions, van Houte beneficially owns 37,270 shares of common stock.
- He also holds 14,431, 12,000 and 37,500 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment, as it's primarily about compliance and transparency.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 04/30/2022 | First quarterly vesting increment for 2,886 RSUs. |
| 07/30/2023 | First quarterly vesting increment for 2,000 RSUs. |
| 07/30/2024 | First quarterly vesting increment for 3,750 RSUs. |
| 10/30/2024 | Date of reported transactions: acquisition and disposal of shares and vesting of RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.